The Binding Site, a specialist protein company based in the United Kingdom, and eBioscience, an Affymetrix business, have announced a multiyear distribution agreement granting the Binding Site exclusive rights to distribute eBioscience’s analyte-specific reagents (ASRs) and CE-marked clinical flow cytometry reagents to hospitals and reference labs.
A leader in immunology and oncology research reagents, eBioscience was established in San Diego in 1999. The company offers a wide selection of antibodies, ELISAs, multiplex solutions, and proteins for immunology, oncology, cell biology, stem cell biology, and clinical markets. The Binding Site is an in vitro diagnostics supplier of special protein reagents and instruments specializing in antibody specificity technology. The company develops products that aid in diagnosis and management of patients with specific cancers and immune disorders, such as primary immunodeficiency disease.
“Our best-in-class full ASR and CE-designated immunology and oncology antibody portfolio is a natural complement to the expertise of the Binding Site,” say Dara Grantham Wright, senior vice president and general manager of the eBioscience business at Affymetrix. “Together we now provide an outstanding solution for clinicians to improve identification, interpretation, and management of clinical hematological malignancies. With this agreement, we strengthen our emphasis on addressing the needs of the growing cancer diagnostics market.”
“Our vision is to lead the way in specialized medical diagnostics, as we do, for example, in multiple myeloma and immunodeficiency,” says Charles de Rohan, chief executive of the Binding Site Group. “We are delighted to be joining forces with eBioscience, one of the most progressive providers of flow cytometry reagents. With our excellent direct sales and support coverage, we look forward to providing more clinical laboratories with this comprehensive portfolio of innovative products.”
“This partnership broadens our cancer-based diagnostic portfolio and allows us to provide a more comprehensive product offering to our customers,” says Doug Kurth, president of the Binding Site Inc. “We will be better positioned to meet the needs of clinicians by capitalizing on eBioscience’s long history of quality flow cytometry reagents and our commitment to cancer diagnostics.”
According to the announcement, the Binding Site began serving eBioscience customers in the United States on December 1, 2014, and will start to serve international customers on February 15, 2015.